
    
      In this clinical trials, patients will be dosed YY-20394 orally at 80mg per day until disease
      progression, unacceptable toxicity, or withdrawal from the study. A treatment cycle is
      defined as 28 days. Drug safety will be evaluated by NCI-CTC AE5.0 every week within 28 days
      after first dose and every 2 weeks in the following cycles. Efficacy will be assessed by
      RECIST1.1 after 2 cycles.
    
  